<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>Basics of Antiplatelets</title>
    <meta charset="utf-8" />
    <meta name="author" content="Anish Sanjay Shah, MD Cardiology Fellow University of Illinois at Chicago" />
    <meta name="date" content="2021-11-16" />
    <script src="antiplatelets_files/header-attrs-2.11/header-attrs.js"></script>
    <link rel="stylesheet" href="xaringan-themer.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">
class: center, middle, inverse, title-slide

# Basics of Antiplatelets
## Cath Conference
### Anish Sanjay Shah, MD<br><span style="font-size: 70%;">Cardiology Fellow<br>University of Illinois at Chicago</span>
### November 16, 2021

---






# Objectives

1. Pathophysiology of atherosclerotic lesions

1. Role of antiplatelet agents in coronary artery disease

1. Types of antiplatelet agents and their mechanism

1. Use cases for antiplatelet agents

---
class: center, middle, inverse
# Pathophysiology

---
background-image: url("plaque-formation.jpg")
background-size: contain

.footnote[
NEJM 2007
]

---
background-image: url("atherosclerosis.jpg")
background-size: contain

.footnote[
Mackman et al 2018
]

---
### Atherosclerosis

- Leads to narrowing of the arterial lumen, allowing for tissue ischemia to occur with increased metabolic demands (e.g. coronary ischemia with angina)

- Increases risk for plaque rupture or erosion `\(\rightarrow\)` intravascular thrombi

- Arterial thrombi are _white clots_ which are primarily platelets, stabilized by fibrin and tissue factor (that triggers coagulation cascade)

- Both platelet activation and coagulation cascade occur in parallel

---
class: center, middle, inverse
# Mechanisms

---
background-image: url("platelet.jpg")
background-size: contain

.footnote[
Nature 2007
]

---
background-image: url("mechanisms.jpg")
background-size: contain

.footnote[
Patrono et al 2017 (JACC)
]

---
### Pharmacology 

There are three general, non-redundant pathways for platelet activation. 

1. `\(TXA_{2}\)` (thromboxane) pathway

1. `\(ADP\)` (adenosine diphosphate) pathway

1. Thrombin-activated pathways

All transduce __independent__ signals for platelet activation, and are thus __additive__.

---
### Pathways

| Pathway | Description |
|:--- |:--- |
| Cyclooxygenase-1 inhibitors | `\(COX1\)` suppresses `\(TXA_{2}\)` |
| `\(P2Y_{12}\)` inhibitors | `\(ADP\)` receptor blockade |
| Protease-activated receptor inhibitors | `\(PAR1\)` and `\(PAR4\)` ligand blockade (normally activated by thrombin-catalyzed proteolysis) |

---
### Agents

| Mechanism | Subtypes | Drugs |
| --- | --- | --- |
| `\(COX\)` inhibitors | type 1 | aspirin | 
| `\(COX\)` inhibitors | type 2 | NSAIDs | 
| `\(P_{2}Y_{12}\)` receptor blockers | irreversible | ticlopidine, clopidogrel, prasugrel |
| `\(P_{2}Y_{12}\)` receptor blockers | reversible | ticagrelor, cangrelor |
| `\(GPII_{a}III_{b}\)` inhibitors | monoclonal Ab | abciximab |
| `\(GPII_{a}III_{b}\)` inhibitors | synthetic | eptifibatide, tirofiban |
| `\(PDE\)` inhibitors | | dipyridamole, cilostazol | 
| `\(PAR\)` inhibitors | type 1 | vorapaxar |

---
class: middle, inverse, center
# Secondary Prevention

---
background-image: url("dapt-usage.jpg")
background-size: contain

---
### Secondary Prevention

.pull-left[
#### Stable Coronary Artery Disease

With no intervention: 

- SAPT with low-dose aspirin
- SAPT with clopidogrel as an _alternative_ 

With PCI (DES):

- DAPT for 6 months

]

.pull-right[
#### Acute Coronary Syndrome

With PCI (DES):

- DAPT for 12 months (and then SAPT)
- Can decrease to 6 months based on bleeding risk

_However, data is increasing for reducing the duration of DAPT._

]

Even with antiplatelet therapy, __2-5%__ of CAD/PAD patients have __MACE__.

---
### Dual Antiplatelet Therapy

| Combination | Indication |
|:--- |:--- |
| aspirin `\(+\)` clopidogrel | elective PCI for stable CAD (due to slower onset of action) |
| aspirin `\(+\)` prasugrel | ACS with planned PCI (higher rate of CABG-related bleeding), no need to preload, contraindicated in CVA, no shown benefit in age `\(\gt\)` 75 years |
| aspirin `\(+\)` ticagrelor | ACS with either PCI or CABG, contraindicated in ICH, 10% side effect of dyspnea |
| aspirin `\(+\)` vorapaxar | unclear benefit, potentially helpful in stable PAD |
| aspirin `\(+\)` dipyridamole | non-cardioembolic ischemic stroke/TIA |


.footnote[
Patrono et al 2017 (JACC)
]

---
class: middle, inverse, center
# Thank You

    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script>var slideshow = remark.create({
"highlightLines": true
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
(function() {
  "use strict"
  // Replace <script> tags in slides area to make them executable
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    var scriptAttrs = scripts[i].attributes;
    for (var j = 0; j < scriptAttrs.length; j++) {
      s.setAttribute(scriptAttrs[j].name, scriptAttrs[j].value);
    }
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();
// adds .remark-code-has-line-highlighted class to <pre> parent elements
// of code chunks containing highlighted lines with class .remark-code-line-highlighted
(function(d) {
  const hlines = d.querySelectorAll('.remark-code-line-highlighted');
  const preParents = [];
  const findPreParent = function(line, p = 0) {
    if (p > 1) return null; // traverse up no further than grandparent
    const el = line.parentElement;
    return el.tagName === "PRE" ? el : findPreParent(el, ++p);
  };

  for (let line of hlines) {
    let pre = findPreParent(line);
    if (pre && !preParents.includes(pre)) preParents.push(pre);
  }
  preParents.forEach(p => p.classList.add("remark-code-has-line-highlighted"));
})(document);</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
